Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

被引:58
|
作者
Eslamparast, Tannaz [1 ,2 ]
Eghtesad, Sareh [2 ]
Poustchi, Hossein [2 ]
Hekmatdoost, Azita [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Dept Clin Nutr & Diet Therapy, Fac Nutr & Food Technol, Natl Nutr & Food Technol Res Inst, 7 West Arghavan St,Farahzadi Blvd,POB 19395-4741, Tehran 1981619573, Iran
[2] Univ Tehran Med Sci, Liver & Pancreatobiliary Dis Res Ctr, Digest Dis Res Inst, Tehran 1411713135, Iran
关键词
Nonalcoholic fatty liver disease; Dietary supplementation; Treatment;
D O I
10.4254/wjh.v7.i2.204
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is currently known as the most common liver problem, characterized by excessive lipid accumulation in hepatocytes, which may progress to other liver diseases such as nonalcoholic steatohepatitis, hepatic tissue fibrosis, liver cirrhosis, and failure or hepatocellular carcinoma. Since NAFLD is positively associated with the development of obesity, insulin resistance, and ultimately type 2 diabetes mellitus, it is often regarded as the hepatic manifestation of the metabolic syndrome. No pharmacologic treatment has yet been proven for this disease. For most patients with presumed or confirmed NAFLD, the only proven strategy is to offer lifestyle advice that can lead to sustained weight loss. Since insulin resistance, oxidative stress, inflammation, and necro-apoptosis are involved in NAFLD pathogenesis, it seems that every potential therapeutic agent should target one or some of these pathologic events. There are many well known anti-oxidants, anti-inflammatory, and insulin sensitizer dietary supplements which have shown beneficial effects on NAFLD improvement in animal and human studies. The purpose of this review is to explore the existing evidences on dietary supplements considered to have hepatoprotective properties, and to present some proposed mechanisms by which they may protect against NAFLD.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [1] Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease
    Tannaz Eslamparast
    Sareh Eghtesad
    Hossein Poustchi
    Azita Hekmatdoost
    World Journal of Hepatology, 2015, (02) : 204 - 212
  • [2] Recent advances in the treatment of non-alcoholic fatty liver disease
    Mendes, FD
    Lindor, KD
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 29 - 35
  • [3] Pediatric non-alcoholic fatty liver disease: Recent advances
    Della Corte, Claudia
    Vajro, Pietro
    Socha, Piotr
    Nobili, Valerio
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (04) : 419 - 422
  • [4] PEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE: RECENT ADVANCES AND CHALLENGES
    Poggiogalle, E.
    Olivero, G.
    Anania, C.
    Ferraro, F.
    Pacifico, L.
    MINERVA PEDIATRICA, 2010, 62 (06) : 569 - 584
  • [5] Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
    Abenavoli, Ludovico
    Larussa, Tiziana
    Corea, Alessandro
    Procopio, Anna Caterina
    Boccuto, Luigi
    Dallio, Marcello
    Federico, Alessandro
    Luzza, Francesco
    NUTRIENTS, 2021, 13 (02) : 1 - 10
  • [6] Dietary Intervention in Non-Alcoholic Fatty Liver Disease
    Abenavoli, Ludovico
    Milic, Natasa
    JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS, 2013, 113 (02) : 211 - 211
  • [7] Recent concepts in non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    DIABETIC MEDICINE, 2005, 22 (09) : 1129 - 1133
  • [8] Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances
    Lau, Jennie Ka Ching
    Zhang, Xiang
    Yu, Jun
    JOURNAL OF PATHOLOGY, 2017, 241 (01): : 36 - 44
  • [9] Treating inflammation to combat non-alcoholic fatty liver disease
    Wiering, Leke
    Tacke, Frank
    JOURNAL OF ENDOCRINOLOGY, 2023, 256 (01)
  • [10] The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
    Yan, Ruike
    Cao, Yanli
    BIOMEDICINES, 2025, 13 (01)